Helomics® Corporation and Ariel Precision Medicine, Inc. Intend to Establish Laboratory Agreement to
Helomics® Corporation and Ariel Precision Medicine, Inc.Intend to Establish Laboratory Agreement to Advance Clinical Genomics in Precision Medicine Applications
Companies announce their intent to explore collaboration opportunities in a wide range of initiatives and establish a regional hub for Precision Medicine
PITTSBURGH– October 9, 2017 - Helomics® Corporation (Helomics), a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotechnology industries, and Ariel Precision Medicine, Inc. (Ariel), an integrated genomics and digital health company enabling early treatment and targeted management of complex chronic diseases, today announced their intention to establish a laboratory services agreement and explore opportunities to collaborate on a wide range of scientific and commercial initiatives.
Helomics intends to serve as a clinical reference laboratory for Ariel, supporting commercial applications of Ariel’s proprietary, clinically integrated genomic assay. Additionally, in pursuit of a shared vision to make the Pittsburgh region a leader in Precision Medicine, Helomics and ARIEL will explore opportunities to work together in research and clinical applications, toestablish a Next-Generation Sequencing (NGS) ”hub” and to provide products and services to life-sciences organizations within the region and beyond.
The terms and conditions established between Ariel and Helomics were not disclosed.
Gerald J. Vardzel Jr., President and CEO of Helomics said, “We are extremely excited about partnering with Ariel to serve as the clinical laboratory for their genomics assay. Ariel is a leader in developing solutions for complex medical conditions to improve disease diagnosis and, ultimately patient care. Both companies share a desire to make Western Pennsylvania a leader in the development of research and clinical NGS applications in Precision Medicine to positively impact patient outcomes. We are looking forward to working with Ariel to make this vision a reality.”
Jessica Gibson, President and CEO of ARIEL stated, “We are excited to be working together and believe that Ariel and Helomics have very complimentary products and services that will provide significant value for patients and clinicians. Pittsburgh is so rich in technology, professional expertise and cutting edge science that syndicating efforts around advancing life sciences and healthcare technology is a natural and necessary progression. Helomics and Ariel share a Precision Medicine vision for Pittsburgh and, by leveraging Helomics’ sophisticated CLIAlaboratory, have the opportunity to accelerate the research and clinical offerings of emergingtechnologies, and we are looking forward to making an impact.”
About Helomics Corporation
Helomics® is an precision diagnostic company and integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace. In addition to our proprietary precision diagnostics for oncology, Helomics offers boutique CRO services that leverage our patient-derived tumor models, coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and a proprietary bioinformatics platform to provide a tailored solution to our client’s specific needs.
Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains state-of-the-art, CLIA-certified, clinical and research laboratories.
For more information, please visit: www.helomics.com .
About Ariel Precision Medicine, Inc.
Ariel is an integrated genomics and digital health company delivering precision medicine solutions enabling the early diagnosis, prognosis and management of complex chronic diseases. Ariel’s technologies can lead a paradigm shift from targeting single gene (Mendelian) genetics to using multifaceted, complicated gene to gene interactions that interface with familial and environmental factors to provide a more comprehensive view of disease trajectory and precise therapeutic options. Results from next generation sequencing of more than 1500 genetic targets are integrated with a patient’s symptoms and complex medical information using systems modeling, machine learning and other advanced reporting technology to create decision support tools. The process compares a patient and his or her disease behavior against databases of well-mapped, complex disease patterns to help determine both the underlying cause of the disease and the optimal treatment plan. Ariel’s headquarters are in Pittsburgh, PA, with additional offices in Chicago and Los Angeles.
For more information, please visit: www.arielmedicine.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
For more information regarding Helomics Corporation, please contact:
Jane Vardzel, Marketing and Digital Media Coordinator
For more information regarding ARIEL Precision Medicine, Inc., please contact:
Jessica Gibson, CEO
ARIEL Precision Medicine, Inc. email@example.com
Sources: Helomics Corporation and ARIEL Precision Medicine, Inc.